Imerys

FY20: recovery in end-markets gaining pace

19/02/21 -"Imerys published FY20 results which were better than expected. It saw a catch-up in volume demand by Q4 and maintained a positive price mix. Well managed opex resulted in an EBITDA margin at 18% in ..."

PDF page sample
Pages
55
Language
English
Published on
19/02/21
Download
You may also be interested by these reports :
07/11/25
Heidelberg Materials reported Q3 sales and Results from Current Operations (RCO) in line with expectations, driven by disciplined pricing and ...
07/11/25
In the first nine months of 2025, Buzzi reported consolidated net sales of €3,406.2 million, up 7.0% from €3,184.3 million a year earlier. The ...
07/11/25
CRH delivered another strong quarter, with total revenues rising 5% year-on-year to $11.1 billion, up from $10.5 billion in Q3 2024. Net income ...
06/11/25
Wars, AI, Stimulus — Cement Takes Off

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO